Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis    NOVN   CH0012005267

NOVARTIS (NOVN)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Novartis : KHCC, Novartis Pharma AG sign cooperation agreement

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/04/2017 | 03:51pm CEST

Oct. 04--AMMAN -- HRH Princess Ghida Talal, the chairperson of the King Hussein Cancer Foundation's board of trustees, on Tuesday signed a memorandum of understanding (MoU) with the CEO of Novartis Pharma AG, Bruno Strigini, the Jordanian News Agency, Petra, reported.

The memorandum aims at enhancing cooperation between the two corporations in scientific research."Research is considered a vital and integrated part at [KHCC] to improve the diagnostic and treatment process of cancer patients, which is in-line with the centre's efforts that is aimed towards saving our patients," Princess Ghida said.

The memorandum was signed in the presence of Asem Mansour, director general of KHCC and Hekmat Abdul Razzaq, deputy director general of KHCC.

___

(c)2017 the Jordan Times (Amman, Jordan)

Visit the Jordan Times (Amman, Jordan) at www.jordantimes.com

Distributed by Tribune Content Agency, LLC.

© Tribune Content Agency, source Regional News

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NOVARTIS
07/14NOVARTIS : Michael Cohen contacts were more extensive than previously disclosed
AQ
07/13NOVARTIS : Played Down Ties to Trump Lawyer Michael Cohen, Report Says
DJ
07/13NOVARTIS : disputes U.S. senators' report on Cohen contract
RE
07/13NOVARTIS AG : half-yearly earnings release
07/13NOVARTIS : to Drop Anti-Infectives Research Programs and Lay Off 140
AQ
07/12NOVARTIS : Findings from Novartis Yields New Findings on Pharmaceutical Research..
AQ
07/12NOVARTIS : Shares Lifted by Prospect of Gilenya Exclusivity in US -- Update
DJ
07/12NOVARTIS : Patent Issued for Systems and Methods for Subretinal Delivery of Ther..
AQ
07/12NOVARTIS : Patent Issued for Aqueous Pharmaceutical Composition Containing a Bio..
AQ
07/12NOVARTIS : Patent Issued for Resolution Enhancement of OCT Images during Vitreor..
AQ
More news
News from SeekingAlpha
07/15BIOTECH ANALYSIS CENTRAL PHARMA NEWS : Cytodyn's Acquisition, Novartis Exits Ant.. 
07/15WEEK IN REVIEW : Tasly Biopharma Completes Pre-IPO Round At $1.9 Billion Valuati.. 
07/13ResTORbio - Leading The Charge Against Aging Related Diseases 
07/13Senate report contradicts Novartis' version of events with former Trump attor.. 
07/13Novartis takes issue with Senate version of interactions with Cohen 
Financials ($)
Sales 2018 51 857 M
EBIT 2018 12 814 M
Net income 2018 10 344 M
Debt 2018 14 171 M
Yield 2018 3,71%
P/E ratio 2018 16,66
P/E ratio 2019 19,73
EV / Sales 2018 4,16x
EV / Sales 2019 3,98x
Capitalization 201 B
Chart NOVARTIS
Duration : Period :
Novartis Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Technical analysis trends NOVARTIS
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 89,7 $
Spread / Average Target 14%
EPS Revisions
Managers
NameTitle
Vasant Narasimhan Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Werner Kirsch Chief Financial Officer
John Tsai Chief Medical Officer
Srikant Madhav Datar Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS-3.93%201 464
JOHNSON & JOHNSON-8.56%337 763
PFIZER3.59%219 534
ROCHE HOLDING LTD.-5.60%200 973
MERCK AND COMPANY11.76%169 193
AMGEN11.60%129 635